Abstract: Numerous brands and types of artificial tears are available on the market for the treatment of dysfunctional tear syndrome. Past literature has focused on comparing the components of these products on patient's clinical improvement. The wide array of products on the market presents challenges to both clinicians and patients when trying to choose between available tear replacement therapies. Different formulations affect patients based on etiology and severity of disease. In order to provide an unbiased comparison between available tear replacement therapies, we conducted a literature review of existing studies and National Institutes of Health clinical trials on commercially available, brand name artificial tears. Outcomes evaluated in each study, as well as the percent of patients showing clinical and symptomatic improvement, were analyzed. Fifty-one studies evaluating different brands of artificial tears, and their efficacy were identified. Out of the 51 studies, 18 were comparison studies testing brand name artificial tears directly against each other. Nearly all formulations of artificial tears provided significant benefit to patients with dysfunctional tear syndrome, but some proved superior to others. From the study data, a recommended treatment flowchart was derived.
Introduction
Dysfunctional tear syndrome (DTS), commonly known as dry eye syndrome, describes the multifactorial condition where the ocular system fails to produce good quality tears or a sufficient amount of tears to keep the eye moisturized. 1 Human tears, composed of electrolytes, water, proteins (eg, antibodies, lysozymes), and lipids, function to moisturize the ocular surface and minimize damage to the corneal epithelium. These components come together to form three distinct layers: 1) the outermost lipid layer, 2) a middle aqueous layer, and 3) the epithelium-covering mucoid layer. Dysfunction in any of these layers can yield tear film instability and hyperosmolarity. 2, 3 External causes of such dysfunction are widespread including environmental factors, systemic diseases, and medications. [4] [5] [6] [7] [8] [9] [10] [11] [12] DTS is among the most commonly encountered ocular morbidities, affecting as many as 15%-25% of individuals over the age of 65 and up to 6% of adults over the age of 40. [12] [13] [14] [15] Inadequate lubrication results in ocular surface damage and discomfort. In addition to increasing the risk of ocular infection, DTS can cause irreversible scarring and fibrosis due to unprotected corneal epithelial exposure. [16] [17] [18] [19] Many clinicians have begun to treat the condition with increased vigilance.
14 Furthermore, prompt intervention can offer substantial benefits with regards to quality of life and comfort. 20 Artificial tears are currently the mainstay of therapy of DTS. They account for at least $540 million in annual sales globally and are the preferred first-line therapy due to their noninvasive nature and low side effect profile. 14, 21, 22 However, a dizzying array of brands and marketing strategies have made it a challenge for patients and clinicians alike to identify the product that best suits individual patients.
Data compilation
Data from all studies were compiled into one group. Each study had its own means of data collection and definition for successful treatment with artificial tears. Methods for collecting the subjective data were mainly through questionnaires including McMonnies Dry Eye Symptom survey, 24 Ocular Surface Disease Index (ODSI) questionnaire, 18 impact of dry eye on everyday life (IDEEL) questionnaire, 25 Visual Analogue Scale, Salisbury Eye Evaluation (SEE) questionnaire, 26 Ocular Discomfort Severity questionnaire, direct brand comparison with drop preference selection, quality of life through the Measure Yourself Medical Outcome Profile-2 (MYMOP-2), 27 and Dry Eye Disease Comfort Assessment Score. Several studies also utilized custom questionnaires. [28] [29] [30] [31] Objective data took the form of ocular surface staining using various dyes, usually fluorescein and rose bengal. Additionally, comparative data was collected through analysis of a variety of other parameters including Schirmer's test, tear break-up time, posttherapy corneal topography, tear meniscus volume, mucinous layer analysis with rose bengal staining, tear osmolarity, lipid layer thickness (LLT), improvement of visual acuity, conjunctival hyperemia, Ocular Protection Index (OPI) (examining the tear break-up time divided by the interblink interval), number of eyelid parallel conjunctival folds, blinking time analysis through the OPI 2.0 system, Global Staining Score, the TearLab Osmolarity System, and tear film normalization test (measurement of lines of improvement in visual acuity after administration of artificial tears). 28, 29, [32] [33] [34] [35] [36] Commercially available tear film substitutes
To provide maximum utility for the patient and clinician, commercially available artificial tears were identified and categorized based on active ingredient (Tables S1-S5) . Other over-the-counter treatments for DTS including gels, ointments, and sprays/mists were included in the compilation (Table S4) . Active ingredients and preservatives were verified via package inserts for each product. Artificial tears were divided into groups based on active ingredients including hydroxypropyl methylcellulose (HPMC), carboxy methylcellulose (CMC), polyvinyl alcohol, homeopathic remedies, and the liquid polyols. A final group was made for other delivery methods including gel/ointments, spray/mist over-the-counter treatments, and the prescribed ophthalmic insert, Lacrisert ® (Valeant, Bridgewater, NJ, USA). Lacrisert was included in the study because its composition and active ingredient mimic those of some artificial tears.
Results
A total of 18 articles comparing subjective and objective outcomes of artificial tear brands were identified in our 
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Artificial tears potpourri: a literature review literature search. All articles were written in English or translated to English from other languages, including German, Spanish, and Chinese. The outcomes from these studies are summarized in Table 1 . Many of these studies utilized different parameters to determine treatment efficacy.
Refresh versus Systane
The first study compared Systane ® (Alcon Laboratories, Inc., Fort Worth, TX, USA) to Refresh Tears ® (Allergan, Irvine, CA, USA) in 87 patients with dry eyes over a 6-week period. 37 Both investigators and patients were blinded to the artificial tear being used. The study evaluated the conjunctival/ corneal staining and a custom symptom questionnaire at days 7, 14, 28, and 42. At days 14 and 28, patients using Systane ® showed significantly improved conjunctival staining compared to patients using Refresh Tears ® . At days 14 and 42, patients using Systane also had significantly decreased temporal corneal staining compared to patients using Refresh. Furthermore, subjective symptomatic improvement was significantly increased in patients using Systane when compared to those using Refresh.
Another study comparing Systane versus Refresh products utilized a three-way cross-over study design 30 A reduced sum score of corneal staining and a reduction of corneal staining from baseline were only observed in the Refresh Liquigel ® group (P=0.008 and P=0.019, respectively). Patient's tear preference and comfort were also analyzed in this study; however, patients were not blinded to the artificial tear assigned. Using one eye for each artificial tear, patient preference was recorded 5 minutes after application with 36% of patients preferring Refresh and 24% preferring Systane. Limited value may be drawn from the subjective component of this study since unilateral symptoms may have been present in the study participants.
The largest of the studies comparing artificial tears was completed in Germany. 39 The study was a multicenter, 
Refresh versus Refresh
Allergan funded a project studying the efficacy of Refresh Tears ® , Refresh Ultra ® , and Refresh Optive ® in relieving the signs and symptoms of dry eye. 43 A total of 37 participants completed the study; 18 with a history of dry eye and 19 controls without a history of dry eye. In this three-way cross-over study, each patient used each artificial tear formulation for 2 weeks while TBUT, tear evaporation, osmolarity, tear structure, and patient symptoms were evaluated. To assess the effects on blurring, distortion, and contrast sensitivity, Allergan funded a study to quantify changes in visual acuity after administration of Refresh Liquigel ® and Refresh Celluvisc ® , two products of thicker consistency than most artificial tears. 42 In 20 normal subjects without a history of dry eye disease, artificial tears were applied at different time points followed by testing of contrast sensitivity via a computer controlled stimulus. Both artificial tears significantly reduced contrast sensitivity immediately after application (P0.001); however, Refresh Celluvisc ® did so to a greater degree (P0.001).
Further 45 Blink ® Tears proved superior to Systane ® Ultra in both TBUT (P=0.003) and improvement in visual acuity (P0.001). 46 
Blink
® Tears was also compared to Refresh Optive ® in a trial of 51 patients with a history of dry eye. 31 The primary goal of this Allergan-sponsored study was to improve subjective symptoms on the Dry Eye Disease Comfort Assessment questionnaire score over a 16-day period. No statistical analysis was performed on these data, but changes between the two groups appeared similar with a mean decrease on the questionnaire score of 1. 41 46 Drop comfort grading was measured using a 0-9 scale, with 0 representing the highest level of comfort. The design was a randomized, double-masked, cross-over study with 20 patient participants. After drop administration, the comfort scores were 0.7±1. 26 50 After 4 weeks of treatment, patients were evaluated with TBUT, Schirmer's test, and corneal staining as well as via a symptom questionnaire. A total of 37 patients completed the study. Both TBUT and Schirmer testing improved in the GenTeal group but not in the Tears Naturale ® group (P=0.27). Both artificial tears were rated as excellent for tolerability and convenience. Subjective symptoms were not different between the two treatments. Table 2 summarizes the clinical improvement of dry eye subjects based on objective and subjective criteria used on each study included in this review. Due to the heterogeneity of criteria used on these studies, a percent of improvement was calculated for each of the artificial tears evaluated. The percent of improvement was calculated based on the amount of subjects with symptomatic and clinical improvement with respect to the total subjects treated. 
Clinical improvement

Discussion
In all 18 head-to-head studies, patients with dry eyes had clinical improvement both immediately after application and over the long term when using tear replacements. This occurred in both preserved and preservative-free artificial tear formulations. With head-to-head comparisons, the results varied greatly and often depended on the funding source. To no surprise, each study that was industry sponsored found the respective company's artificial tear to be most effective. Further, the newer artificial tears, Refresh Optive ® and Systane ® Ultra, definitively outperformed the older Refresh Tears ® and Systane ® in both subjective and objective tests. Interestingly, Soothe ® dramatically increased the lipid layer of the tear film compared to its Systane and Refresh counterparts. A lipid layer under 60 nm indicates a higher likelihood of having dry eye symptoms. Conversely, having a LLT greater than 75 nm decreases symptoms, and generally, a thicker lipid layer directly correlates with decreased symptoms. 50 This is an important finding since studies have shown that a deficient lipid layer is the most common cause of DTS. 52 After reviewing all the studies, we elaborated a set of recommendations that may help both the physician and the patient in decision making when a tear replacement therapy is needed. Due to the lack of standardization and bias from industry-funded studies, these recommendations are not intended to be conclusive and final, but a good resource based on the comparative data we gathered on the discussed head-to-head studies.
Recommendations
Our recommendations for suggested drop brands in each of the respective categories is based upon both the number of studies completed on these brands as well as the trials that compared their efficacy against other brand name artificial tears (see Tables 1 and 2 ). Due to the heterogeneous data 
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Moshirfar et al available and lack of standardization between studies, the recommendations made are not intended to be definite and should be individualized based on disease severity and patient's expectations. This is a step approach, initiating therapy with the most studied artificial tears. Treatment recommendations (summarized in Figure 1 ) are as follows:
Step 1 The treatment algorithm allows for initial therapies to be divided into three categories of drops based on the active ingredient: CMC-based, HPMC-based, and hyaluronic acid-based. In a recent comprehensive review of the active ingredients contained in artificial tears, the above listed ingredients have been shown to be the most beneficial in improving patient comfort levels. 53 For each of these categories, the most studied brands of artificial tears were recommended. Additionally, Systane ® and Refresh Tears ® have been well studied and have been beneficial in the treatment of mild dry eye syndrome (see Tables 1 and 2 ).
Step 2
Systane
® Ultra and Soothe ® have both been shown in clinical research to out-perform the CMC/HPMC/hyaluronic acid-based formulations listed in Step 1 (see Tables 1 and S1 ). In the instance that initial therapy fails to adequately control the symptoms of DTS, either of these two drops should be considered as the next therapy.
Steps 3 and 4
In the event that standard artificial tears fail to adequately abate the patient's symptoms and/or in the case of severe DTS, lid malposition, or exposure keratopathy, the implementation of additional therapies such as gels, ointments, liposomal sprays, is indicated. 37, [54] [55] [56] [57] [58] [59] [60] [61] These therapies may need to be implemented earlier based on severity of disease.
Frequency/duration
Based on the duration and frequency of artificial tear use reported in all the studies referenced in Tables 1 and 2 , a mean of 3.47 doses/day over a period 60.1 days was established. Thus, our recommendation would be to use the artificial tears three to four times per day over a period of 2 months before transitioning to the next step. If artificial tear use extends beyond four to six times per day, then a preservative-free formulation should be used. 
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Artificial tears potpourri: a literature review Preserved versus preservative-free As seen in Tables S1-S5, many different tear replacement formulations include preservatives, but not all preservatives have the same effects. The most commonly used preservative was benzalkonium chloride (BAK). BAK has more antimicrobial activity than any other preservative in both animal and human subjects. However, BAK has been shown to damage the corneal epithelium and disrupt the tear film immediately after administration, which directly contradicts the goal of artificial tears. 63, 64 Some of the newer preservative compounds appear to have a better safety profile than BAK but do not entirely prevent corneal epithelium damage. 65 50, 63, 66 Since most of the corneal changes occur when the preservatives reach high concentrations, if one chooses to use a tear replacement with preservatives, daily use should be limited to four to six times. 62 Due to the risk of contamination, if a preservative-free artificial teardrop is chosen, single dose vials are recommended over multidose administration bottles. 67 Increased cost represents another downside to preservative-free artificial tears compared to those with preservatives. All things considered, a choice between preservative-free and preserved artificial tears should be discussed on an individual basis between physician and patient.
Limitations
The US is currently the epicenter of clinical research on DTS as it has been previously documented to conduct 70.8% of the registered clinical trials around the world which focused on dry eye. 23 The data presented in this paper may not be applicable in a global setting, as the American diet, and cultural and daily activities may play a role in the development of DTS and its corresponding treatment. With growing research in other countries, such as Japan, Australia, UK, and the Netherlands, treatment of DTS with artificial tears will progressively be refined on a global scale. 68 Furthermore, the research that has been presented in this article is based on a nonregulated health product, and the US permits distribution of artificial tears without any data revealing positive efficacy. 68, 37 Any research investments made into this field may be affected by financial interests of the investigators and call into question the integrity of the outcomes, which may have influenced our recommendations. A recent meta-analysis of the comprehensive research on dry eye disease revealed that the pharmaceutical industry sponsored 78% of 185 clinical trials on this topic in the US. 68 For this reason, care should be taken when analyzing and applying data from industry-funded studies. Independent, unbiased research must increase on a worldwide level in order to more objectively and accurately elucidate the management of DTS.
In addition, this review article addressed a myriad of subjective and objective data with a multitude of data collection methods and varying result parameters, including dosing and length of treatment phase. For these reasons, further statistical analyses of improvements were not completed in this paper, but our study does suffer from lack of statistical backing. Furthermore, many of the individual papers which contributed to our information pool validated their data prior to their release. In future clinical trials, standardization of measurement instruments as well as dosage and time of treatment could enrich the generalizability of the outcomes and lead to a more consistent review of resultant data.
Finally, our study provides recommendations based on comparative studies previously published in the literature. Most of the artificial tears available in the market, as seen in Tables 2 and S1 -S5, were not included in the recommendations since they have not been included in comparative studies. We recognize that the recommendations made are still a good guide for clinicians and patients when initiating DTS therapy based on the data available.
Conclusion
With the expansive amount of commercially available artificial tear options, specific recommendations are needed to help guide both the clinician and patient. Although limited by the lack of congruent methodology throughout the included studies and heterogeneous population, this paper aimed to provide unbiased recommendations based on the available data and should be a step towards the standardization of future studies regarding artificial tears. Utilizing both direct comparison and patient improvement following artificial tear use, a treatment flowchart was created (Figure 1) . Ultimately, artificial tear selection should be individualized to the patient's specific needs. In the future, a standardized method to evaluate dry eye, as well as efficacy of artificial tear treatment, will allow for improved recommendations to be formed.
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